Extended Wear Sensors for Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests new, long-lasting sensors designed to monitor blood sugar levels in individuals with Type 1 or Type 2 diabetes. The goal is to collect data from these sensors to understand their performance in daily life. The trial suits those diagnosed with diabetes for at least six months and willing to use these sensors regularly. As an unphased trial, participants contribute to innovative research that may improve diabetes management.
What prior data suggests that these extended wear sensors are safe for diabetes patients?
Research has shown that new long-lasting sensors for diabetes are safe and accurate. One study found these sensors provided reliable blood sugar readings for up to 180 days. Users reported comfort, and no major safety issues emerged. Another study demonstrated that a similar sensor, the G7, was also safe and effective, delivering accurate readings for over 10 days. These findings suggest that the sensors being tested are likely safe for use with minimal risk of side effects.12345
Why are researchers excited about this trial?
Next Generation Extended Wear Sensors are unique because they offer a longer wear time compared to current continuous glucose monitors (CGMs). Most CGMs need to be replaced every 7 to 14 days, but these new sensors aim for an extended duration, potentially making diabetes management more convenient and less intrusive. Researchers are excited because longer wear times could mean fewer disruptions for users and more consistent glucose monitoring, which can lead to better management of diabetes and improved quality of life.
What evidence suggests that these extended wear sensors are effective for diabetes?
Research has shown that continuous glucose monitoring (CGM) sensors can significantly aid in diabetes management. These devices reduce both the frequency and duration of low blood sugar episodes and improve overall blood sugar control. For individuals with type 2 diabetes, CGM use increased the time their blood sugar remained within the target range by 10.3%. A review of studies involving people with type 1 diabetes showed improvements in key blood sugar measures, such as A1c, which indicates average blood sugar levels over several months. These sensors provide real-time feedback, helping users make better daily decisions without needing to prick their fingers. In this trial, all participants will use the Next Generation Extended Wear Sensors to evaluate their effectiveness in managing diabetes.678910
Are You a Good Fit for This Trial?
This trial is for people aged 2 to 80 years old who have either type 1 or type 2 diabetes. Participants should be able to use a continuous glucose sensor and follow study instructions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants wear the Next Generation Extended Wear Sensors and data is collected
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Next Generation Extended Wear Sensors
Trial Overview
The study is testing new extended wear glucose sensors that can be worn longer than current models, collecting data on how well they work in people with diabetes.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
All subjects will wear the sensor. Each subject and subject's parent/guardian/caregiver (if applicable) may insert and tape (if applicable) the study glucose sensors once trained or have them inserted and taped (if applicable) by the trained investigational center staff.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medtronic MiniMed, Inc.
Lead Sponsor
Citations
Continuous Glucose Monitoring Sensors for Diabetes ... - PMC
CGM devices have been proved to improve safety and effectiveness of diabetes therapy, reduce hypoglycemia incidence and duration, and decrease glycemic ...
Wearable Continuous Glucose Monitoring Sensors
With a 9% MARD, it is the first and only CGM system that can be used to make daily diabetes treatment decisions without finger pricking [57,58].
3.
type1strong.org
type1strong.org/blog-post/6-best-continuous-glucose-monitors-for-2026-most-accurate-and-latest-devices-reviewed6 Best Continuous Glucose Monitors for 2026
Dexcom G7 (Best overall for most users) Wear time: 15.5 days Accuracy: MARD 8.2% (adults), 8.1% (children), and 7.7% for ages 2 to 6. Eversense 365 reduces the ...
4.
diabetesjournals.org
diabetesjournals.org/care/article/42/8/1593/36184/Clinical-Targets-for-Continuous-Glucose-MonitoringClinical Targets for Continuous Glucose Monitoring Data ...
individuals with type 2 diabetes increased their TIR by 10.3% (from 55.6% to 61.3%) after 24 weeks of CGM use with slight reductions in TBR. ...
Continuous Glucose Monitoring, Mobile Technology ... - NCBI
In a 2023 meta-analysis of 22 RCTs that included participants with T1D, there was an overall improvement in A1c, TIR and TBR (49).
The PROMISE Study
These data show the next-generation Eversense CGM system had sustained accuracy and safety up to 180 days, with an improved calibration scheme ...
Evaluation of MiniMed Next Generation Extended Wear ...
Next Generation Extended Wear Sensors. This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age. subjects will wear ...
8.
diabetesincontrol.com
diabetesincontrol.com/the-safety-and-efficacy-of-next-generation-g7-cgm-over-g6/The Safety and Efficacy of Next-Generation G7 CGM Over G6
The seventh-generation (G7) continuous glucose monitor provides accurate and safe glucose readings during 10.5 days of use.
Beyond glucose monitoring: Multi-analyte biosensing and ...
Next-generation CGMs can be engineered as multianalyte sensors that can simultaneously also detect other diabetes associated biomarkers like ketones, lactate, ...
8 Next-Gen CGMs In Development You Need To Know About
The Biolinq Shine sensor is designed for people with type 2 diabetes who are not on insulin, and it is the first CGM to ditch the traditional insertion needle ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.